COMMUNIQUÉS West-GlobeNewswire

XYMOGEN XPERIENCE Dedicated Exclusively to Elevating Women’s Health
07/08/2024
A renowned lineup of experts will address wellness insights core to women’s health beyond hormones ORLANDO, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- XYMOGEN ® is excited to announce its XYMOGEN XPERIENCE Fall 2024 (XX [...]
Asensus Surgical 2024 Special Meeting of Stockholders Is Adjourned
07/08/2024
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, today announced that the Company’s [...]
Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference
07/08/2024
CELEBRATION, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief [...]
Groundbreaking Voice of the Patient Report for pediatric low-grade glioma (pLGG) published by Pediatric Brain Tumor Foundation
07/08/2024
Report documents the experiences of pLGG patients, survivors, their families, and caregivers to inform future drug development for pLGG, the most common brain tumor type in children NEW YORK, Aug. 07, 2024 (GLOBE [...]
BioVie Inc. Announces Reverse Stock Split
06/08/2024
Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024 CARSON CITY, Nev., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”) today announced that the [...]
Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024
06/08/2024
NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for [...]
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
06/08/2024
Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage [...]
Travere Therapeutics to Present at Upcoming Investor Conferences
06/08/2024
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August: 2024 Wedbush PacGrow [...]
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
06/08/2024
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today [...]
STERIS Announces Financial Results for Fiscal 2025 First Quarter
06/08/2024
Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6% As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03 Fiscal 2025 outlook [...]
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
06/08/2024
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported [...]
Cellectis publie ses résultats financiers du deuxième trimestre 2024
06/08/2024
Statuts de médicament orphelin et de médicament pour une maladie pédiatrique rare accordés par la FDA et statut de médicament orphelin accordé par la Commission européenne à UCART22 pour le traitement de la leucémie [...]
Cellectis Provides Financial Results for the Second Quarter 2024
06/08/2024
ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL ODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatment Cash position of $273 million as of June 30 [...]
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
06/08/2024
Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDA Expanded sales coverage for Libervant™ (diazepam) Buccal Film for [...]
Globus Medical Reports Second Quarter 2024 Results
06/08/2024
AUDUBON, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2024. Worldwide net [...]
CooperCompanies Announces Release Date for Third Quarter 2024
06/08/2024
SAN RAMON, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report third quarter 2024 financial results on Wednesday, August 28, 2024, at 4:15 PM ET. Following the release [...]
Certara Reports Second Quarter 2024 Financial Results
06/08/2024
Reiterates Full Year 2024 Financial Guidance RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the [...]
Supernus Announces Second Quarter 2024 Financial Results
06/08/2024
Net sales of Qelbree ® increased 92% in the second quarter of 2024, compared to the same period in 2023. $59.4 million and $104.5 million of net sales in the second quarter and first six months of 2024, respectively. [...]
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
06/08/2024
Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor Initiated global clinical trial collaboration [...]

Pages